Biocom, a Korea-based AI healthcare startup, has successfully raised KRW 3 billion (approximately USD 2.25 million) in a pre-Series A funding round, led by East Gate Partners, Lotte Ventures, and the Korea SMEs and Startups Agency. The investment underscores Biocom’s technological innovation and competitive edge in the digital healthcare sector.

The company specializes in delivering personalized nutrition and healthcare management services to individuals in a “sub-health” state—a condition characterized by mild, non-specific symptoms that do not constitute a defined illness. Biocom’s offerings include bio-analytical services and health supplements, and it provides comprehensive metabolic function analysis, hair mineral analysis, and food sensitivity analysis.

Aiming to achieve KRW 7 billion (approximately USD 5.25 million) in revenue this year, Biocom is recognized for its robust market potential and technological capabilities. The recent funding will be allocated towards enhancing AI technology, expanding services, and preparing for entry into global markets.

Biocom has been selected for the Scaleup TIPS program, supported by East Gate Partners, recognizing the startup’s strong execution and potential for scale. Lotte Ventures, the venture capital arm of Lotte Group, plans to integrate Biocom’s services with Lotte’s B2B offerings to fuel revenue growth.

Jung Hee-yong, CEO of Biocom, commented, “At the heart of healthcare services are data quality and application. Biocom manages an extensive database of over 2.8 million bio-data records, utilizing this data to offer tailored nutrition and lifestyle solutions. This wealth of data is invaluable for developing distinctive AI services and continuous enhancements.”

Jung added, “Our technology enables early detection and effective management of sub-health conditions, helping to prevent diseases and improve public health. In partnership with our investors, we are strengthening our market presence and targeting an IPO by 2027.”

Sub-health is defined as a precursory state to illness where individuals experience various mild symptoms, representing a ‘gray zone’ between health and disease. Biocom’s services are strategically focused on managing this crucial intermediate stage effectively.